How India Exports Acyclovir to the World

Acyclovir, an antiviral medication, has been a staple in the U.S. pharmaceutical market for decades. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for acyclovir, indicating a well-established generic presence. Notably, the first generic approvals date back to the late 1980s, underscoring the drug's long-standing availability. The absence of recent first generic approvals suggests market saturation.

Regarding import alerts, as of March 2026, there are no specific FDA import alerts targeting acyclovir products from India. This indicates that Indian manufacturers have maintained compliance with FDA standards, facilitating uninterrupted exports to the U.S. market. Given that 74.7% of India's acyclovir exports are destined for the United States, this compliance is crucial for sustaining trade relations.

In the European Union, acyclovir is authorized through national procedures, with marketing authorizations granted by individual member states. The European Medicines Agency (EMA) oversees harmonization efforts to ensure consistent safety and efficacy standards across the EU. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates acyclovir, ensuring compliance with national guidelines. Manufacturers exporting to these regions must adhere to Good Manufacturing Practice (GMP) requirements as outlined by the EMA and MHRA, which encompass stringent quality control measures and regular inspections.

Acyclovir is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of acyclovir products worldwide.

In India, acyclovir is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, acyclovir is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national and international regulations.

The primary patents for acyclovir have long expired, leading to a robust generic market with significant competition. This competitive landscape has contributed to the drug's affordability and widespread availability.

In June 2025, the NPPA conducted a review of antiviral drug prices, including acyclovir, to assess market dynamics and ensure fair pricing. In September 2025, the CDSCO issued updated guidelines for the export of pharmaceutical products, emphasizing stricter quality control measures to align with international standards. In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of acyclovir, highlighting its continued relevance in treating viral infections.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API and KSM requirements are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese exports can lead to shortages and increased costs for Indian manufacturers.

Efforts to reduce this dependency have been initiated through the Production Linked Incentive (PLI) scheme, launched in October 2024, aiming to bolster domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. Despite these initiatives, challenges such as cost competition from Chinese manufacturers, who have reportedly slashed prices of certain APIs by up to 50% in September 2025, continue to undermine India's self-sufficiency efforts.

The export data for Acyclovir from India indicates a high supplier concentration, with the top five exporters accounting for 87.4% of the total export value. Notably, MYLAN LABORATORIES LIMITED alone holds a 45.5% share, amounting to $57.3 million USD. This concentration poses a significant single-source risk, as any operational or regulatory issues affecting these key suppliers could disrupt the entire supply chain.

The PLI scheme, introduced to reduce import dependence and encourage domestic production, has seen some progress with the establishment of new manufacturing units. However, the effectiveness of this scheme in diversifying the supplier base for Acyclovir remains to be fully realized. Continuous monitoring and support are essential to ensure that these initiatives lead to a more resilient supply chain.

Recent geopolitical tensions have significantly impacted global supply chains. In March 2026, the closure of the Strait of Hormuz due to military conflicts led to a substantial decline in maritime transit, affecting about 20% of the world's daily oil supply. This disruption caused oil prices to surge, with Brent crude surpassing $100 per barrel on March 8, 2026. Such events have cascading effects on the pharmaceutical industry, leading to increased manufacturing and transportation costs.

Additionally, the Red Sea and the Strait of Hormuz have experienced disruptions due to regional conflicts, further complicating shipping routes and increasing transit times. These geopolitical challenges underscore the need for robust risk management strategies to mitigate potential supply chain disruptions.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Acyclovir to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to boost domestic manufacturing of APIs and KSMs, thereby reducing reliance on imports.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact supply chains and develop contingency plans accordingly.

• Invest in Alternative Shipping Routes: Explore and invest in alternative shipping routes and methods to mitigate risks associated with traditional chokepoints like the Strait of Hormuz.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to stringent regulatory standards to prevent disruptions due to compliance issues.

RISK_LEVEL: HIGH